RxDoctor Payments Data

Maria Wasique, MD

Internal Medicine · Ashburn, VANPI 1700811239

Payments from drug & device makers

$700in general payments, 2019–2025

Across 43 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$250
  • Lilly USA, LLC$150
  • AstraZeneca$48
  • Abbott$45
  • Pfizer$39
  • Exact Sciences$36
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$68698%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$700 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$43,643
Medicare patients
98
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$33,574
OzempicSemaglutide26$30,059
JanuviaSitagliptin Phosphate14$22,302
MounjaroTirzepatide15$19,550
Synjardy XrEmpagliflozin/Metformin Hcl14$19,129
Janumet XrSitagliptin Phos/Metformin Hcl11$12,411
Rosuvastatin Calcium52$2,303
Levothyroxine Sodium100$1,100
Valsartan38$1,037
Atorvastatin Calcium119$916
Venlafaxine Hcl ErVenlafaxine Hcl12$728
Duloxetine Hcl21$671
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide28$636
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$606
Omeprazole56$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$14$52,70338 claims
Novo NordiskOzempic$250$30,05926 claims
Lilly USA, LLCMounjaro$150$19,55015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Ashburn

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →